elevation oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. we make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. together with our peers we work towards a future in which each unique genomic testing result can be matched with a purpose-built precision medicine to bring clarity to every cancer treatment journey. our lead candidate, seribantumab, inhibits tumor growth driven by nrg1 fusions and is currently being clinically tested in the phase 2 crestone study for patients with tumors of any origin that have an nrg1 fusion. learn more about crestone at www.nrg1fusion.com. elevation oncology is backed by aisling capital, vertex ventures hc, qiming venture partners usa, driehaus capital management, and bvf partners.
Company profile
Ticker
ELEV
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
14ner Oncology, Inc.
SEC CIK
Corporate docs
Subsidiaries
Elevation Oncology Securities Corporation ...
IRS number
841771427
ELEV stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
5 Apr 24
S-8
Registration of securities for employees
6 Mar 24
8-K
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
6 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
8-K
Other Events
23 Jan 24
8-K
Departure of Directors or Certain Officers
22 Jan 24
8-K
Other Events
5 Jan 24
8-K
Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business Achievements
2 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Sep 23
Latest ownership filings
SC 13G
Frazier Life Sciences Public Fund, L.P.
9 Apr 24
4
Joseph J Ferra Jr
19 Mar 24
4
Alan B. Sandler
4 Mar 24
4
Julie M Cherrington
4 Mar 24
3
Alan B. Sandler
4 Mar 24
3
Julie M Cherrington
4 Mar 24
4
Valerie Malyvanh Jansen
20 Feb 24
4
Tammy Furlong
20 Feb 24
4
David Dornan
20 Feb 24
4
Joseph J Ferra Jr
20 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 54.88 mm | 54.88 mm | 54.88 mm | 54.88 mm | 54.88 mm | 54.88 mm |
Cash burn (monthly) | 17.15 mm | (no burn) | 3.64 mm | 4.76 mm | 4.45 mm | 5.15 mm |
Cash used (since last report) | 117.15 mm | n/a | 24.87 mm | 32.50 mm | 30.42 mm | 35.21 mm |
Cash remaining | -62.28 mm | n/a | 30.01 mm | 22.37 mm | 24.46 mm | 19.67 mm |
Runway (months of cash) | -3.6 | n/a | 8.2 | 4.7 | 5.5 | 3.8 |
Institutional ownership, Q3 2023
92.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 49 |
Opened positions | 8 |
Closed positions | 6 |
Increased positions | 12 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 17.93 bn |
Total shares | 44.77 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tang Capital Management | 4.00 mm | $2.65 bn |
Millennium Management | 3.03 mm | $2.01 bn |
venBio Partners | 2.91 mm | $1.93 bn |
Aisling Capital IV | 2.88 mm | $0.00 |
Aisling Capital Management | 2.83 mm | $1.88 bn |
venBio Global Strategic Fund III | 2.54 mm | $4.19 mm |
Qiming U.S. Healthcare GP II | 2.37 mm | $30.20 mm |
Qiming U.S. Ventures Management | 2.37 mm | $1.57 bn |
Biotechnology Value Fund L P | 2.31 mm | $0.00 |
BVF | 2.31 mm | $1.53 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
16 Mar 24 | Joseph J Ferra Jr | Common Stock | Payment of exercise | Dispose F | No | No | 4.39 | 4,773 | 20.95 k | 85,680 |
16 Mar 24 | Joseph J Ferra Jr | Common Stock | Option exercise | Acquire M | No | No | 0 | 12,562 | 0.00 | 90,453 |
16 Mar 24 | Joseph J Ferra Jr | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 12,562 | 0.00 | 62,809 |
29 Feb 24 | Julie M Cherrington | Stock Option Common Stock | Grant | Acquire A | No | No | 4.41 | 55,000 | 242.55 k | 55,000 |
29 Feb 24 | Alan B. Sandler | Stock Option Common Stock | Grant | Acquire A | No | No | 4.41 | 55,000 | 242.55 k | 55,000 |
News
HC Wainwright & Co. Reiterates Buy on Elevation Oncology, Maintains $6 Price Target
9 Apr 24
Elevation Oncology Presents Preclinical Proof-Of-Concept Data For HER3-ADC Program At AACR Annual Meeting 2024
8 Apr 24
HHS Says In 2025, All People With Medicare Part D Will Benefit From A $2,000 Cap On Annual Out-Of-Pocket Prescription Drug Costs
26 Mar 24
JMP Securities Reiterates Market Outperform on Elevation Oncology, Maintains $7 Price Target
7 Mar 24
Wedbush Maintains Outperform on Elevation Oncology, Raises Price Target to $8
7 Mar 24
Press releases
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
8 Apr 24
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
6 Mar 24
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
5 Mar 24
Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors
4 Mar 24
Elevation Oncology to Participate in Upcoming Investor Conferences
28 Feb 24